CN1711087A - 用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂 - Google Patents

用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂 Download PDF

Info

Publication number
CN1711087A
CN1711087A CNA2003801030038A CN200380103003A CN1711087A CN 1711087 A CN1711087 A CN 1711087A CN A2003801030038 A CNA2003801030038 A CN A2003801030038A CN 200380103003 A CN200380103003 A CN 200380103003A CN 1711087 A CN1711087 A CN 1711087A
Authority
CN
China
Prior art keywords
retinal
alkyl
aryl
retinopathy
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801030038A
Other languages
English (en)
Chinese (zh)
Inventor
P·G·科林寇
D·P·宾加曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1711087A publication Critical patent/CN1711087A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2003801030038A 2002-11-12 2003-10-30 用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂 Pending CN1711087A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42557402P 2002-11-12 2002-11-12
US60/425,574 2002-11-12

Publications (1)

Publication Number Publication Date
CN1711087A true CN1711087A (zh) 2005-12-21

Family

ID=32313018

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801030038A Pending CN1711087A (zh) 2002-11-12 2003-10-30 用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂

Country Status (12)

Country Link
US (3) US20060074100A1 (https=)
EP (1) EP1560583A4 (https=)
JP (1) JP2006512318A (https=)
KR (1) KR20050086526A (https=)
CN (1) CN1711087A (https=)
AU (1) AU2003287349B2 (https=)
BR (1) BR0316206A (https=)
CA (1) CA2504460A1 (https=)
MX (1) MXPA05004485A (https=)
RU (1) RU2352337C2 (https=)
WO (1) WO2004043352A2 (https=)
ZA (1) ZA200503237B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101239929B (zh) * 2007-02-09 2013-04-17 中国科学院上海药物研究所 曲古抑菌素a衍生物及其制备方法和用途

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
KR20070057822A (ko) * 2004-08-09 2007-06-07 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
BRPI0610368A8 (pt) 2005-05-05 2015-09-08 Glaxosmithkline Ip Dev Ltd Modulação de enzima e de receptor
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AU2006272497B2 (en) * 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
KR20080091297A (ko) * 2006-02-07 2008-10-09 아스텔라스세이야쿠 가부시키가이샤 Ｎ-히드록시아크릴아미드 화합물
WO2007113644A2 (en) * 2006-04-05 2007-10-11 Orchid Research Laboratories Limited New hdac inhibitors
US8962825B2 (en) * 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
JP2010513223A (ja) * 2006-12-15 2010-04-30 アステラス製薬株式会社 Ｎ−ヒドロキシアクリルアミド化合物
JP2008266321A (ja) * 2007-03-28 2008-11-06 Santen Pharmaceut Co Ltd フェニレンジアミン誘導体を有効成分とする眼圧下降剤
KR102341446B1 (ko) * 2016-09-29 2021-12-21 네이처와이즈 바이오테크 & 메디칼스 코포레이션 안구 질병을 치료하는 방법
WO2019089573A1 (en) * 2017-10-30 2019-05-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR20190099952A (ko) * 2018-02-20 2019-08-28 주식회사 종근당 포도막염의 예방 또는 치료를 위한 조성물
WO2019246509A1 (en) * 2018-06-22 2019-12-26 Mohan Rajiv R Methods and compositions for promoting wound healing with decreased scar formation after glaucoma filtration surgery
WO2020102599A1 (en) * 2018-11-14 2020-05-22 Vanderbilt University Treating intraocular retinoblastoma with inhibitors of histone modification
RU2769320C1 (ru) * 2020-12-28 2022-03-30 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) Способ получения производных N-гидроксибутанамида

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
BR9914779A (pt) * 1998-10-13 2001-07-03 Fujisawa Pharmaceutical Co Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso
US6953783B1 (en) * 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
EP1167346A4 (en) * 1999-04-06 2003-07-23 Ono Pharmaceutical Co DERIVATIVES OF 4-AMINOBUTANIC ACID AND MEDICINES THAT CONTAIN THESE DERIVATIVES AS ACTIVE ACTIVE SUBSTANCES
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1443928B1 (en) * 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
CN1711086A (zh) * 2002-11-12 2005-12-21 爱尔康公司 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101239929B (zh) * 2007-02-09 2013-04-17 中国科学院上海药物研究所 曲古抑菌素a衍生物及其制备方法和用途

Also Published As

Publication number Publication date
AU2003287349B2 (en) 2009-04-23
MXPA05004485A (es) 2005-11-23
KR20050086526A (ko) 2005-08-30
EP1560583A4 (en) 2010-09-22
AU2003287349A1 (en) 2004-06-03
EP1560583A2 (en) 2005-08-10
US20040092558A1 (en) 2004-05-13
US20100048608A1 (en) 2010-02-25
WO2004043352A3 (en) 2004-07-15
JP2006512318A (ja) 2006-04-13
BR0316206A (pt) 2005-09-27
CA2504460A1 (en) 2004-05-27
WO2004043352A8 (en) 2005-06-30
US20060074100A1 (en) 2006-04-06
ZA200503237B (en) 2006-06-28
RU2005118107A (ru) 2006-01-20
WO2004043352A2 (en) 2004-05-27
RU2352337C2 (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
CN1711087A (zh) 用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂
JP2006512318A5 (https=)
US12167999B2 (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US20090203614A1 (en) Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
US20110082200A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
CN1509183A (zh) 蛋白酶体抑制剂在治疗干眼疾病中的用途
CN1298304A (zh) 用于预防和治疗由眼底组织细胞病变引起的疾病的药物组合物
CN1447688A (zh) 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法
WO1997041864A1 (en) Ophthalmic preparations
JP2010510292A (ja) 抗痙攣医薬組成物
MXPA05004486A (es) Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular.
US20040220227A1 (en) Remedies for allergic eye diseases
CN1681510A (zh) Pde ⅳ抑制剂治疗血管生成的用途
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
EP3272360A1 (en) Pharmaceutical composition comprising polypeptide
JP2008506768A (ja) Ｃｏｘ−２選択的阻害剤とｌｔｂ４受容体アンタゴニストを組み合わせて用いる炎症および疼痛を治療するための組成物
HK40068749A (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
HK1110768B (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
HK1243347B (en) Pharmaceutical composition comprising polypeptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication